>I like REGN's efficacy data and the fact that REGN might include Lucentis as control arm in P3.<
As previously posted (#msg-10907088), I thought the VEGF-Trap phase-1 data were impressive for an evaluation six weeks after a single treatment. What I find baffling is that SNY had no interest in pursuing VEGF-Trap in ophthalmology despite having paid big money in 2003 to acquire the rights in all indications.
REGN – By the way, VEGF-Trap for AMD is a slightly different formulation—not just a different dose—than VEGF-Trap for cancer. This may come in handy if (as rkrw suggested on SI) docs try to aliquot the cancer product à la Avastin to save money when treating AMD.
Market Data 
Markets 
AI
